India’s Healthcare Business Daily

Link copied to clipboard
Expert's Corner

Why Insurance Coverage Should Be Guided by Clinical Evidence, Quality and Patient Safety

An expert in the field, Dr. Girdhar Gyani, Director General, Association of Healthcare Providers (AHPI India), explains insurance coverage and the possible guidelines.

The General Insurance Council’s recent recommendation to extend insurance coverage to only five robotic-assisted surgical procedures has brought an important question into focus: how should insurance coverage decisions be made when medical technology and clinical practice are evolving rapidly?

The intention behind defining a fixed set of procedures may be to bring greater consistency and predictability to reimbursement. Yet, such lists risk creating unintended limitations when clinical evidence and medical practice extend beyond those categories. This is particularly significant when the IRDAI’s 2024 Master Circular requires insurers to cover modern treatment methods wherever they are medically necessary.

The issue, therefore, is not whether robotic-assisted surgery should be covered indiscriminately. It is whether coverage decisions should be determined by a narrow procedural classification or guided by clinical evidence, quality, patient safety and medical necessity.

Healthcare Delivery Has Evolved. Coverage Must Keep Pace

India’s healthcare system has changed substantially over the past decade. Doctors can diagnose disease earlier, plan treatment with greater precision, and choose options that did not exist when many insurance frameworks were designed. Yet, coverage decisions are still guided by reimbursement models that were built for a less complex era of healthcare.

That gap has consequences. Insurance decisions do not merely settle claims; they determine whether patients can access the treatment their doctors consider most appropriate.

Modern medicine increasingly recognizes that treatment decisions cannot be standardized solely around a diagnosis. The stage of disease, comorbidities, surgical risk, recovery prospects, and the patient’s circumstances all influence the choice of treatment. Such clinical judgement lies at the heart of good care.

In surgery, technology now enables greater precision, enhanced visualization and improved control in complex procedures. As healthcare becomes more sophisticated, coverage frameworks must evolve accordingly.

Clinical decisions are guided by what is most appropriate for a patient, whereas, reimbursement decisions determine what will be financially supported. The two should ideally reinforce one another. When reimbursement frameworks fail to keep pace with clinical evidence, patients risk losing access to treatments their doctors consider appropriate.

Coverage Cannot Stop Where the List Ends

This gap between clinical decision-making and reimbursement policy is becoming increasingly visible as healthcare adopts newer technologies and treatment approaches.

 Clinical scrutiny is essential for any treatment or technology, but once reimbursement is confined to a limited set of procedures, access can become disconnected from clinical judgement.

When a clinically supported procedure falls outside the list, the patient may be denied coverage even when doctors recommend it as the better option. Reimbursement policy then begins to dictate treatment, rather than support it.

The Real Measure Is What Treatment Delivers

The case for broader assessment is not based on technology for its own sake. It rests on outcomes.

Clinical studies have associated robotic-assisted surgery in selected settings with greater precision, improved visualisation, a 25 per cent reduction in operative time, and a 30 per cent decrease in intraoperative complications. Robotic-assisted minimally invasive procedures increased from 4.2 per cent to 14.8 per cent. These figures do not justify blanket coverage, but they do make a narrow five-procedure limit difficult to defend without wider clinical review.

Cost matters, but the price of a procedure is only one part of the treatment journey. Fewer complications, shorter hospital stays, less follow-up care, and faster recovery can change the overall value of an intervention and the patient’s experience.

For India, this matters beyond the hospital. Non-communicable diseases already strain family incomes, caregiver responsibilities, and workforce participation. When appropriate treatment is delayed or placed beyond a patient’s reach, those costs do not disappear. Families, caregivers and the wider economy absorb them.

This is why reimbursement decisions cannot be made through financial assessments alone.

They require clinical context, informed by clinicians and hospitals who understand outcomes, patient selection and the realities of care delivery. Better policy emerges when these perspectives are brought together through a transparent process of evidence review and consultation.

Ultimately, it is an opportunity to ensure that coverage decisions are informed by the full weight of available evidence, shaped through meaningful stakeholder consultation and focused on patient outcomes rather than procedural classifications.

The true purpose of health insurance is not simply to finance treatment, but to enable access to the most appropriate care when it is medically required.

Where evidence is strong and clinical need is clear, coverage should follow. That is the balance India now needs.